Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again

    JJIM APAC Search Results

    Listening...

    Types

    • Contact Us

      Read more

    • Terms of Service

      Read more

    • Terms and Conditions | JCA Standard Trading Terms (AU & NZ)

      Review the JCA Standard Trading Terms for Australia and New Zealand, effective until 30 April 2025. Includes detailed conditions for orders, deliveries, pricing, payment, and customer responsibilities.
      Read more

    • Chris Rieger

      Chris Rieger has served as President and Representative Director of Johnson & Johnson (J&J) Innovative Medicine Japan (Legal entity name: Janssen Pharmaceutical K.K.) since June 2025. In this role, he oversees the entire pharmaceutical business in Japan. As a member of J&J Innovative Medicine’s Asia Pacific Leadership Team, Chris is committed to transforming the Japanese market, the largest in the region, and successfully launching innovative medicines that address the unmet needs of patients in Japan.
      Read more

    • Victor Karam

      Victor is the Vice President of Finance & CFO, Innovative Medicine Asia Pacific. In this role, Victor provides financial leadership to the Asia Pacific region and collaborates with the APAC Leadership Team to drive growth, profitability, and successful business outcomes.
      Read more
    • About us

      Legal Notice

      Read more
    • About us

      Privacy Policy

      Read more

    • Lihui Yu

      Lihui Yu is Senior Director of Commercial Quality at Johnson & Johnson Innovative Medicine, Asia Pacific and a member of the Asia Pacific Leadership Team.
      Read more

    • Andrew Wheatley

      Andrew leads the Innovative Medicine Communication and Public Affairs team (C&PA) across Asia Pacific to deliver powerful strategies that support patients, enhance access and accelerate the business. The team is also charged with building and protecting the long-term reputation of J&J Innovative Medicine with both internal and external stakeholders.
      Read more

    • Miemie Strydom

      Miemie leads the Asia Pacific New Business Development (NBD) team in the evaluation of opportunities across all therapeutic areas to support global and regional BD activities, executing local partnerships and leading key alliance management activities. She is a member of the J&J Innovative Medicine Asia Pacific Leadership Team (APLT).
      Read more